Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
These drugs are glucagon-like peptide-1 (GLP-1) receptor agonists that can make you feel less hungry and feel full sooner
Compared to classical gastroprotective peptides such as sucralfate or proton pump inhibitors (PPIs), it acts via a completely different pathway: restoration of mucosal microcirculation rather than acid reduction or formation of a mechanical protective layer
View Study [3]"IGF-I and IGFBP-3 transport in the rat heart" Boes M, Dake BL, et al., 2003 Finding: This study showed that LR3 IGF-I can bypass IGF binding proteins that normally sequester IGF-1, demonstrating why LR3 has greater bioactivityit reaches target tissues more effectively than native IGF-1
Some of the most clinically relevant findings: 12.7% mean weight loss at 12 months, with nearly 60% of patients achieving 10% weight loss 18.9% reduction in total fat mass, including continuous visceral fat reduction Although lean mass decreased initially (as expected during weight loss), it stabilized after 7 months Muscle strength improved significantly (+4.1 kg handgrip strength), highlighting that muscle function can be preservedand even enhanceddespite reductions in lean mass Sarcopenic obesity prevalence decreased from 49% to 33% Resting energy expenditure normalized for lean mass increased between months 7 and 12, suggesting improved metabolic efficiency Why does this matter
US$ 20.52
US$ 25.26
US$ 22.33
US$ 22.73
US$ 27.60
